LOTA S. ZOTH - Corporate Board Profile

INOVIO PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2020-03-27	Lota S. Zoth joined our Board in January 2019 and qualifies to serve on our Board as a result of her years of experience in senior financial roles in a variety of commercial-stage companies over a 35-year career. She currently serves as the chairman of the board of directors of the publicly held biopharmaceutical company Zymeworks, Inc. and also serves on the board of directors of the publicly held biopharmaceutical company Lumos Pharma, Inc. (formerly NewLink Genetics Corporation). Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.’s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served in financial executive roles at PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in accounting from Texas Tech University.
2021-03-25	Lota S. Zoth joined our Board in January 2019 and qualifies to serve on our Board as a result of her years of experience in senior financial roles in a variety of commercial-stage companies over a 35-year career. She currently serves as the chairman of the board of directors of the publicly traded biopharmaceutical company Zymeworks, Inc. and also serves on the board of directors of the publicly traded biopharmaceutical companies Lumos Pharma, Inc. and 89bio, Inc. Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.’s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served in financial executive roles at PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in accounting from Texas Tech University.
2022-03-25	Lota S. Zoth Age: 62 Director Since: 2019 Director The members of the Audit Committee currently are Lota S. Zoth (Chair), Simon X. Benito and Ann C. Miller. The members of the Compensation Committee currently are Wendy L. Yarno (Chair), Ann C. Miller, Jay P. Shepard and Lota S. Zoth. Director Compensation Table Lota S. Zoth Fees Earned or Paid in Cash ($): 77,000 Stock Awards ($): 112,140 Option Awards ($): 124,805 Total ($): 313,945
2023-03-28	Lota S. Zoth Age: 63 Director Since: 2019 Director The members of the Audit Committee currently are Lota S. Zoth (Chair), Simon X. Benito and Ann C. Miller. The members of the Compensation Committee currently are Wendy L. Yarno (Chair), Ann C. Miller, Jay P. Shepard and Lota S. Zoth. Director Compensation Table Lota S. Zoth Fees Earned or Paid in Cash ($): 77,500 Stock Awards ($): 35,910 Option Awards ($): 40,434 Total ($): 153,844
2023-11-28	Directors and Named Executive Officers: Lota S. Zoth
2024-04-11	Lota S. Zoth Age: 64 Director Since: 2019 The members of the Audit Committee currently are Lota S. Zoth (Chair), Simon X. Benito and Jay Shepard. The members of the Compensation Committee currently are Wendy L. Yarno (Chair), Ann C. Miller and Lota S. Zoth. Director Compensation Table Lota S. Zoth Fees Earned or Paid in Cash ($): 77,500 Stock Awards ($): 20,014 Option Awards ($): 21,171 Total ($): 118,685
2025-04-07	Lota S. Zoth, Age: 65, Director. Committees: Audit Committee (Chair), Compensation Committee (Member). Total compensation: $127,341.